To order this 350+page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Key Market Insights
§ More than 150industry players across the world are presently engaged in evaluating thepotential of nearly 300 next generation immune checkpoint modulators for thetreatment of multiple disease indications
§ The pipeline featuresa variety of marketed / clinical stage therapies, targeting a number ofdifferent types of immune checkpoints and being investigated for administrationvia different routes
§ In the last fewyears, over 600 clinical studies of various types of immune checkpointmodulation-based therapies, involving nearly 90,000 patients across differentcenters / hospitals, have been initiated worldwide
§ In the pursuit ofobtaining an edge within this emerging and highly competitive market landscape,developers are actively exploring the therapeutic potential of novel immunecheckpoints, beyond PD-L1, PD-1 and CTLA-4
§ Over time, big pharma players have initiated product developmentprograms focused on immune checkpoint modulation for treating variousoncological indications, investing significant capital, time and effort
§ Several organizationshave extended financial support to aid research efforts in this domain; thecurrent focus is on investigation of novel immune checkpoint pathways / targets
§ The growing interest in this field is also reflected by the 120+partnerships have been signed in the last two years, involving bothinternational and indigenous stakeholders
§ The future market,based on the revenue generation potential of marketed and late stage therapies,is anticipated to be distributed across different disease areas, mechanisms andkey geographical regions
§ In the long term, theopportunity is likely to be segmented across diverse therapeutic modalities,immune checkpoint targets and routes of administration
For more information,please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
